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Abstract Human malignant gliomas arise from neural
progenitor cells and/or dedifferentiated astrocytes. By
now, they are genetically so well characterized that
several murine glioma models have emerged that faith-
fully reiterate the typical histological features of the
disease. In experimental animals, only one or two
elements of the growth factor/Ras, PI3K/PTEN/PKB,
p53/ARF/HDM2, and p16/Rb/cyclinD/CDK4 pathways
are targeted. In human gliomas, many additional genes
and pathways are targeted due to a most severe mutator
phenotype that leads to the accumulation of countless
epigenetic and genetic alterations. Changes that convey a
growth advantage are selected for, leading to overgrowth
of precursor cell populations with increasingly malignant
tumor cell clones. While murine models represent a
powerful tool for elucidating the role of genetic pathways,
mechanisms of response and resistance to new therapeutic
agents might be fundamentally different due to the high
degree of genomic instability in the human disease. In
fact, little is known about the molecular causes of
genomic instability involved in gliomas, except for the
rare Turcot’s syndrome, O6-methylguanine-DNA methyl-
transferase, and the apurinic/apyrimidinic endonuclease
Ape-1. Novel approaches that selectively exploit funda-
mental metabolic differences between tumor and normal
cells have to consider these fundamental differences
between human disease and presently available, highly
sophisticated animal models.
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The therapeutic dilemma
Many attempts to treat human gliomas, including brain
tumor surgery introduced some 100 years ago, have had
little effect on the prognosis of this disease which is
basically characterized by two biological factors: un-
scheduled cell proliferation and insidious infiltration of
normal brain tissue. Transformed glial cells stepwise
deprive an affected person of critical neuronal functions
such as the ability to perceive properly, reflect, and react
to exogenous and endogenous stimuli. Some of these
deleterious effects are mediated by factors secreted by
glioma cells, e.g., glutamate, interfering with neuronal
function [116]. Even though surgical interventions taking
advantage of sophisticated online imaging and navigation
technology allow MRI-documented “complete” resection
improving local tumor control, the further course of the
disease remains dominated by unchecked tumor cell
infiltration. Glioma cells resist apoptotic stimuli from
external beam radiotherapy and virtually all chemother-
apeutic agents, except for some remarkable responses
observed in the less prevalent cases displaying oligoden-
droglial differentiation. Even so, impressive chemother-
apeutic responses tend to be transient. Emerging new
therapies based on molecular mechanisms such as block-
ing epidermal growth factor receptor (EGFR) [3, 116], the
target of rapamycin (mTOR) [22, 121], protein kinase B
(PKB)/Akt-1 [12], phosphoinositide 3-kinase (PIK-3) [9],
mitogen-activated extracellular signal-regulated kinase
activating kinase (MEK) [24], or focal adhesion kinase
(FAK) [106] should be evaluated by not only their effect
on visible tumor nodules but also their potential to target
the invisible infiltrative component of the disease.
Innovative techniques allowing visualization and quanti-
tation of infiltrating glioma cells are urgently needed for
therapeutic targeting and accurate response assessment.
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Developmental cues for the cellular origin
of gliomagenesis
Embryonic development of the brain
By embryonic day (E) 8, pluripotent stem cells of the
ventricular zone driven by fibroblast growth factor (FGF)
first produce radial glial cells in the intermediate zone
which proliferate and establish scaffolds that act as guides
for neuronal and glial progenitors as they migrate from
the ventricular zone [39, 46, 77]. By E13, the pluripotent
stem cells become progressively more responsive to EGF,
self-renew, and give rise to glial restricted progenitors
(Fig. 1). By E18, the stem cells in the ventricular zone are
responsive only to EGF and produce the glial restricted
PDGFR+ and PDGFR progenitors, which also migrate
from the ventricular zone to the intermediate zone, where
they undergo oligodendroglial or astrocytic differentia-
tion. Oligodendrocyte progenitors can differentiate into
astrocytes, and astrocytes may dedifferentiate into radial
glia [122]. Transformation of radial glial cells into
astrocytes and vice versa appears to be regulated by the
availability of inducing signals rather than by changes in
cell potential [46].
Hypothesis 1: gliomas arise from neural stem
or glial progenitor cells
The identification, within the adult CNS, of neural stem
cells endowed with the capacity for self-renewal and
differentiation into mature astrocytes and neurons re-
vealed an unexpected level of plasticity in the adult brain
[97]. Consequently, the hypothesis emerged that a
transformed neural stem cell or an early glial progenitor
could be the culprit of tumorigenesis. These cells are
localized predominantly in the subventricular zone and
dentate gyrus of the hippocampus; however, their prolif-
erative and migratory potential allows tumor formation to
manifest anywhere in the brain [77]. A premalignant cell
could either first migrate out of the subventricular zone to
the area of the future tumor nidus where it acquires
mutations in cancer-promoting and -progressing genes, or
a precursor cell suffers genetic damage in the subven-
tricular zone and subsequently starts to migrate in one or
several directions. Both scenarios might be operative in
gliomagenesis.
Fig. 1 Embryonic development of glial cells. By embryonic day 8
(E8), FGF-driven pluripotent stem cells of the ventricular zone first
produce radial glial cells in the intermediate zone which proliferate
and establish scaffolds that guide migration of neuronal and glial
progenitors out of the ventricular zone [39, 46, 77]. By E13, the
pluripotent stem cells become progressively more EGF responsive
and give rise to glial restricted progenitors. By E18, the stem cells
in the ventricular zone are responsive only to EGF and produce the
glial restricted PDGFR+ and PDGFR progenitors, which also
migrate from the ventricular zone into the intermediate zone, where
they undergo oligodendroglial or astrocytic differentiation. Oligo-
dendrocyte progenitors can differentiate into astrocytes, and
astrocytes may dedifferentiate into radial glia [122]. Transforma-
tion of radial glial cells into astrocytes and vice versa appears to be
regulated by the availability of inducing signals rather than by
changes in the cell potential [46]
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Hypothesis 2: gliomas arise
from dedifferentiated astrocytes
Mature astrocytes can dedifferentiate into radial glia, not
only at the site of the experimental inoculation of
embryonic cells but also at a distance from the site of
implantation [46, 113]. This suggests that diffusible
factors acting across long distances can change the fate
of a cell and that mature astrocytes retain the ability to
respond to these factors [77]. Thus, in gliomagenesis,
genetic mutations may convert a mature astrocyte into a
more immature state of proliferation and migration,
possibly facilitated by unspecific stimulation by growth
factors which might—in some cases—be transitorily
released during traumatic and inflammatory conditions.
Therapeutic implications of neural stem cells
In rodent brain tumor models, neural stem cells have been
successfully used to treat experimental gliomas. The gene
for interleukin-4 was stably transferred into C57BL6 J
mouse primary neural progenitor cells injected into
established syngeneic brain glioblastomas, leading to the
survival of most tumor-bearing mice. Similar results were
obtained by implanting immortalized neural progenitor
cells derived from Sprague-Dawley rats into C6 glioblas-
tomas [7]. In another series of experiments, neural stem
cells were found to be capable of tracking both tumor
mass and infiltrating tumor cells following administration
into the contralateral hemisphere or even intravenously
[1]. Similar results were reported in an oligodendroglioma
transgenic mouse model in which neural stem cells
migrated to the tumor after injection at some distance
from the tumor [14]. So far, it is not clear whether stem
cell migration follows a gradient of topic cues, e.g.,
growth factors released from tumor cells, or whether stem
cell survival is dependent upon the secretion of tumor-
derived growth factors, since these cells appear to vanish
following injection into normal brain.
Major pathways of gliomagenesis
A large number of genetic alterations have been detected
and thoroughly catalogued by now in the great variety of
human brain tumors, including the different glioma
subtypes [58]. Although more rare than sporadic tumors,
familial cancer syndromes provided important clues about
the pathophysiology of these neoplasms, illuminating the
role of specific genes and associated pathways. This
concept has also been tested in animal models that have
begun faithfully to reiterate seminal phenotypic features
of the human disease. In glioblastomas, several safeguard
mechanisms are lost due to primary and/or secondary
mutational inactivation, as shown schematically in Fig. 2.
An oncogenic challenge to a normal cell—either from
within or from an external source—induces cell cycle
arrest, DNA repair if possible, or apoptosis. Tumor cells
evade these controls by specifically mutating regulators of
cell cycle and apoptosis. In addition, an endogenous
mutator phenotype leads to the accumulation of countless
genetic and epigenetic alterations which offer a rich and
Fig. 2 Different reaction of a
normal or a cancer cell to
oncogenic stress. Upon an ex-
ogenous or endogenous onco-
genic challenge, a normal cell
induces cell cycle arrest and
either repairs damaged DNA or
undergoes programmed cell
death. A cancer cell cannot
elicit efficient cell cycle arrest
and apoptosis anymore but
manages to survive in spite of
accumulated genomic instabili-
ty
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unique repertoire for each cell to select an even more
malignant phenotype.
Growth factor signaling
In gliomas, PDGFR and EGFR autocrine signaling are
involved in cellular development, proliferation, migra-
tion, and vascularization. PDGF and EGF play important
roles in glial development: EGF in neural stem cell
proliferation and survival, PDGF in glial development
[77]. PDGFR are expressed in most types of gliomas [42],
while EGFR are mainly expressed in glioblastoma
multiforme (GBM) [67]. Of note, PDGFR-A amplifica-
tion was only found in anaplastic oligodendrogliomas
with glioblastomatous features [111]. In highly prolifer-
ating tumor cells, PDGFR-A expression was detected as
well as PDGFR-B expression, which was also found on
endothelial cells [42, 62]. In the adult brain, putative
neural stem cells and glial precursor cells expressing a-
chains of PDGFR are found in the subventricular zone
and scattered throughout the white matter and cerebral
cortex [90, 100]. These distinct cell populations could
well represent glioma precursor cells. The EGFR signal-
ing pathway is necessary for sustained proliferation and
perhaps survival of the neural stem cell compartment.
Approximately 40% of GBMs with EGFR amplification
also express a variant form called EGFRvIII, DEGFR, or
del2–7EGFR [30]. This mutant lacks a portion of the
extracellular ligand-binding domain as a result of genom-
ic deletions that eliminate exons 2–7 in the EGFR mRNA
and which is constitutively autophosphorylated, albeit at a
significantly lower level than in ligand-driven, wild-type
EGFR phosphorylation [25]. DEGFR was aberrantly
located in the endoplasmic reticulum with a half-life
extended severalfold over that of ligand-activated wild-
type receptor, suggesting escape from physiological
regulatory mechanisms utilized for attenuating wild-type
EGFR [26]. The introduction of this truncated receptor
into glioma cells dramatically enhances their tumorige-
nicity in vivo through both increased cellular proliferation
and reduced apoptosis, also conferring resistance against
chemotherapeutic drugs such as cisplatin through modu-
lation of Bcl-XL expression [88]. Growth factor signaling
mediated by critical ligands like EGF and PDGF activates
an intricately complex network of cellular protein
domains modulated by G-protein-coupled receptors and
second messengers [43] which converge at defined
points—crossroads of cell signaling, one of which is
Ras—playing a central role in brain tumorigenesis, as
recently proven by three murine glioma models [19, 24,
45]. Figure 3 shows schematically most critical pathways
or circuits operative in gliomagenesis.
Neurofibromatosis 1 and the critical role
of the Ras pathway
The large neurofibromatosis 1 (NF-1) gene encoding
neurofibromin is considered a mutational hot spot of the
human genome: one out of 3,500 individuals carry a gene
mutation which manifests sporadically as de novo muta-
tion in about 50% of cases outside a familial context [19].
In sporadic malignant gliomas, specific mutations affect-
ing Ras have not been detected; however, high levels of
Ras guanosine triphosphate (GTP) were documented in
astrocytoma cell lines but also in most primary high-grade
astrocytomas in one study, suggesting that the Ras
effector arm is activated possibly by upstream receptor
tyrosine kinase activation, mainly PDGFR and EGFR
[37]. The manifestation of optic nerve glioma, astrocyto-
ma, and glioblastoma in NF-1 patients further underscores
the critical role of the Ras pathway in brain tumorigen-
esis. The disturbed differentiation program in mesenchy-
mal and neuroectodermal precursor cells leads to a wide
clinical spectrum including cognitive deficits, caf-au-lait
maculae, Lisch nodules, craniofacial dysplasia, pheochro-
mocytoma, neurofibromas, and myeloid leukemia.
The NF-1 gene negatively regulates Ras as an
exchange factor converting Ras-GTP to Ras-GDP by its
GTPase-activating (Ras-GAP) domain [19]. RAS-GTP
operates downstream of growth factor receptors at a major
signal transduction crossroad, translating extrinsic mes-
sages into the Raf-MEK-ERK and into either the PI3K-
PKB or the PI3K-Rac-Rho pathway. These signaling
networks are of prime importance in the regulation of cell
survival and migration. The PI3K-Rac-Rho pathway is
involved in cell motility and negatively regulated by
merlin, the neurofibromatosis type II (NF-2) tumor
suppressor that predisposes humans and mice to tumor
development and links the cytoskeleton to the membrane
[103]. Sustained Raf/MEK/ERK signaling represents an
oncogenic challenge that induces a growth arrest and
senescence phenotype mediated by p16INK4A and p14ARF
in normal astrocytes [28]. In INK4A/ARF-deficient
glioblastoma cells, a p21Cip1-dependent pathway has been
postulated that would still operate as a further (redundant)
safeguard mechanism against oncogenic challenges which
needs to be molecularly defined.
The p53-p14ARF-HDM2 and
Rb-p16INK4a-cyclinD-CDK4 pathways
The great majority of malignant brain tumors harbor
inactivating mutations in both the p53- and the Rb-related
pathways, which exert cardinal cellular functions [33, 34,
40, 50, 51, 61]. Each of these functionally linked and
physically interacting proteins can be targeted by the
stochastic mutation selection process during tumorigen-
esis. Many functions have been assigned to the p53
protein. Simplistically, p53 is a short-lived transcription
factor which is upregulated in response to cellular stresses
such as UV and g irradiation, double-strand breaks, and
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cytotoxic drugs that either facilitates DNA repair by
halting the cell cycle or, if the amount of damage is
beyond the cell’s capacity for repair, inducing cell death
[11]. p53 can be viewed as an apoptostat, a protein that
sets a cell’s apoptotic threshold in response to specific
endogenous and exogenous challenges. The Rb-E2F1
pathway controls the transition from the G1 into the S
phase, and mutations that inactivate either Rb or p16INK4a
or activate cyclin-dependant kinase 4 (CDK4) or cyclin D
lead to deregulation of the transcription factor E2F1,
which induces the expression of S-phase-related genes
[40] but also leads directly to the expression of the
antiapoptotic gene Bcl-2 [36]. The counterintuitive find-
ing, however, that E2F-1 was underexpressed on the
protein level in the majority of gliomas will have to be
further analyzed [16]. p16INK4a, which is elevated during
cellular senescence, acquires immortalizing mutational
inactivation during tumorigenesis to evade senescence-
like growth arrest, which can be elicited in response to
sustained activation of the Ras/Raf/MEK/ERK pathway
[73]. Senescence-like growth arrest pathways could be
induced in normal human astrocytes in response to the
expression of Raf-1 in p16INK4a-expressing and -deficient
cells, as discussed above [28].
The p53 and Rb pathways have been extensively
reviewed, including the associated familial cancer syn-
dromes [34, 51, 93]. In this review, the dual role of the
INK4a/ARF locus on human chromosome 9p21 shall
briefly be highlighted. It represents a curious case of a
single genetic locus giving rise to two alternatively
Fig. 3 Signaling network in gliomas. Upregulated growth factor
receptors transmit migratory, growth, and survival signals via the
Ras/MEK/ERK, PI-3 K/PKB, Rac/Rho, and mTOR/S6 K pathways
into the nucleus, where a unique neoplastic transcription program is
induced. Tumor cells have acquired the ability to evade cell cycle
arrest and apoptosis. Moreover, sensing and repair of damaged
DNA is impaired, leading to accumulation of genomic instability.
The tumor suppressor genes that give rise to familial brain tumor
syndromes and induce glial brain tumors are shown in blue boxes
(NF-1, NF-2, PTEN, TSC1,2, p53). Frequently altered cell cycle
and apoptosis regulators in sporadic glioblastomas are also marked
in blue boxes (Rb, p16, p14, p27, HDM 2). The red arrows denote
oncogenic gain of function alterations. The DNA damage sensing
and repair pathway is outlined, also marking the mismatch repair
proteins hMSH2 and hMLH1 that give rise to the rare Turcot’s
syndrome
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spliced transcripts with entirely different reading frames,
p14ARF (in mice p19ARF) and p16INK4a (Fig. 4) [105]. The
human p14ARF gene was accidentally discovered during
gene expression analysis of the methylated and unmethy-
lated p16INK4a gene [79, 84] which was almost simulta-
neously followed by elucidation of the structure and
function of the murine p19ARF protein [94]. Since
p16INK4a negatively regulates CDK4 and p14ARF inhibits
HDM2, blocking rapid ubiquitin-mediated decay of p53,
simultaneous inactivation of both genes by a homozygous
deletion deregulates both the Rb and p53 pathways. The
biological function of this complex locus has been
thoroughly analyzed in gene knockout experiments in
mice, creating animals by either selectively inactivating
p19ARF or p16INK4a or by simultaneously targeting both
genes [55, 59, 101, 102]. These animal data reveal subtle
differences, even arguing for ARF haploinsufficiency to
cooperate with inactivated p16INK4a and giving rise to
metastatic melanoma [102]. Is the INK4A/ARF locus a
glioma inducer? Not really, because the p19ARF-only mice
displayed glioma-type lesions at low frequency [55].
However, in mice and humans alike, this locus efficiently
drives tumor progression. According to a recent study
using highly reliable quantitative real-time polymerase
chain reaction (PCR) to circumvent the difficulty in
assessing homozygous deletions in primary tumor tissue,
some 50% of malignant human gliomas were found to
delete the INK4A/ARF locus, displaying homozygous
deletions that span the reading frame of both genes [61].
This alteration is therefore one of the most frequent
genetic changes operative in glioblastomas that is
acquired during tumor progression and might be linked
to worse prognosis in patients older than 50 years of age
[61]. Similar observations were made in a recent murine
oligodendroglioma and mixed glioma model overexpress-
ing PDGFR-B under both nestin and GFAP promoters.
The Ink4a/ARF / background was not tumorigenic per
se but impressively increased the malignancy from low-
grade to anaplastic stages [21]. Most human malignant
gliomas that retain the INK4a/ARF locus display muta-
tions in other genes of the p53 and the Rb pathway which
both are dysregulated in the great majority of tumors,
leading to an unchecked cell cycle and resistance against
apoptotic stimuli.
The role of phosphatase tensin homology and PKB/Akt-1
Germline mutations of the tumor suppressor gene phos-
phatase tensin homology (PTEN) on chromosome
10q23.3, initially also dubbed MMAC1 and TEP1, define
a familial developmental and cancer syndrome whose
diverse phenotypes have historically been ascribed to the
Cowden-Bannayan syndrome and Lhermitte-Duclos dis-
ease [64, 65, 114]. The clinical spectrum comprises
breast, follicular thyroid and prostate cancers, glioblas-
tomas, meningiomas, skin and intestinal hamartomas,
macrocephaly as well as enlarged cerebellar foliae,
distorted cerebellar cortex, abnormally myelinated axon
bundles, and dysplastic neurons [109]. A Dutch study that
screened Cowden’s disease patients for PTEN mutations
suggests that the phenotype can be caused by at least one
distinct additional gene in kindreds with wild-type PTEN
sequence [89]. Several murine PTEN-deficient mouse
models have been generated that in part reiterate the
clinical phenotype seen in humans [5, 23, 60, 92, 115].
Interestingly, the neurological spectrum of these mice
includes macrocephaly, seizures, and enlarged neuronal
soma size without increased proliferation, while Akt-1 is
hyperphosphorylated [5, 60]. PTEN contains a central
catalytic phosphatase core domain that negatively regu-
lates phosphoinositol-3 kinase (PI3K) by dephosphory-
lating phosphatidylinositol-3,4,5 triphosphate (PtdIns-
3,4,5-P3) and phosphatidylinositol-3,4 diphosphate [75].
In contrast to an earlier report [117, 118], focal adhesion
kinase (FAK) could not be confirmed as a substrate of
PTEN using the same experimental conditions [78].
Furthermore, the dominant negative inhibitor of Tyr-397
FAK was not found to be PTEN-dependent [53, 54]. The
N-terminal domain of PTEN is homologous to the
cytoplasmic proteins tensin and auxilin, which interact
with actin filaments at focal adhesions and clathrin-coated
vesicles. In case of mutant PTEN, the elevated lipid
second messenger PtdIns-3,4,5-P3 is used by PI3K to
hyperphosphorylate protein kinase B (PKB)/Akt [76],
which modulates the activity of proteins that play a
critical role in cell survival, invasion, and proliferation
[47, 78]. The catalytic activity toward phosphoinositide
substrates is required for growth suppression, and PTEN-
mediated growth inhibition is due to a G1 cell cycle block
rather than to induction of apoptosis [35]. The PTEN
structure shows a phosphatase domain similar to that of
protein phosphatases but with an enlarged active site to
accommodate the phosphoinositide substrate, and it also
Fig. 4 Genetic structure of the INK4a/ARF locus on chromosome
9p21. The p16INK4a gene is composed of exons 1a, 2, and 3, while
the human p14ARF (p19 in mice) uses a different promoter of exon
1b about 20 Kb upstream of exon 1a. The genomic sequences of
both transcripts are entirely different, giving rise to two distinct
small cell cycle regulatory proteins, because exon 1b uses an
alternative reading frame
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reveals that PTEN has a C2 domain [63]. The PTEN C2
domain binds phospholipid membranes in vitro, and
mutation of basic residues that could mediate this reduces
PTEN’s membrane affinity and ability to suppress the
growth of glioblastoma tumor cells. PTEN is also a
powerful inhibitor of cell motility which was found to be
independent of its catalytic domain [78] and might be
linked to the N-terminal tensin and auxilin homology
domains. Mutant PTEN might be linked to an aggressive
clinical course [68, 99]. On the other hand, human and
murine tumors with an activated PI3K/PTEN/Akt path-
way might be exquisitely sensitive to rapamycin, a
macrolid antibiotic that downregulates mTOR and poten-
tially opens a new therapeutic window for these tumors
[22, 121]. Of note, the tumor suppressor genes TSC1 and
TSC2 that give rise to hereditary tuberous sclerosis—
mainly a hamartomatous developmental disorder with
occasional manifestation of giant-cell astrocytomas—are
negative regulators of the mTOR pathway (Fig. 3) [87].
Murine glioma models mimicking the human disease
Striking progress in cancer genetics and transgenic and
knockout technologies has allowed the creation of animal
models that faithfully reflect most phenotypic hallmarks
of the human disease. Several models have recently been
presented that highlight the critical role of the cancer
genes defined in the human disease and draw our
attention to the developmental origin of the different
glial neoplasms and the effect of growth factor signaling.
A classification scheme based on genetically engineered
gliomas in mice has been recently presented that
summarizes the histopathological findings in relation to
genetic manipulations [72].
The oligodendroglioma and mixed-glioma mouse
In a cell culture and murine model, it was recently shown
that PDGF autocrine stimulation dedifferentiated cultured
astrocytes and induced oligodendrogliomas and oligoas-
trocytomas from neural progenitors and astrocytes [21].
These experiments were performed using Ink4a-Arf+/+
and Ink4a-Arf/ mice, showing that deletion of this dual
tumor suppressor locus was not required for PDGF-
induced glioma formation. The INK4a-Arf-null back-
ground, however, led to a more malignant phenotype with
areas of necrosis and neovascular proliferation in the
PDGF-b-induced oligoastrocytomas and oligoden-
drogliomas. In an earlier report, brain tumors could be
induced in mice using a similar rationale based on
recombinant platelet-derived growth factor beta-chain
retrovirus which stimulated PDGFR alpha expression
within an autocrine loop [119, 120]. In this model, tumors
were more malignant, displaying characteristics of glio-
blastoma multiforme or a primitive neuroectodermal
tumor. The consistent expression of nestin suggested that
they were all derived from an immature neuroglial
progenitor. PDGFR might be linked to oligodendroglial
differentiation, since in another model, transduction of
Ink4a-ARF-deficient neural progenitor cells with mutant
DEGFR induced glioblastomas but not oligoden-
drogliomas (personal communication, Monika Hegi).
The RAS-Akt glioma mouse
In this transgenic model, genes encoding activated forms
of Ras and Akt were transferred to astrocytes and neural
progenitors in mice in a tissue-specific manner [45].
Neither activated Ras nor Akt alone was found sufficient
to induce gliomas; however, the combination of activated
Ras and Akt induced high-grade gliomas with the typical
histological features. These tumors manifested after
transducing neural progenitor cells but not differentiated
astrocytes.
The NF-1-p53 glioma mouse
Three critical factors constituted the basis for this model:
firstly, NF-1 knockout mice display increased levels of
gliosis; secondly, p53 is mutated in human astrocytomas;
and thirdly, NF-1 patients develop astrocytomas. This
model was generated by a gene knockout strategy [95].
Instead of transferring mutant Ras into a precursor cell,
the NF-1 gene neurofibromin, which negatively regulates
Ras as a Ras-GAP, was used to generate this mouse
model by crossing NF-1-deficient mice with heterozygous
p53 knockout mice. Both genes lie on the same chromo-
some only 7 cM apart, and a recombinant mouse line was
selected which harbors both genes in the cis position.
Thus, the second step of inactivating the wild-type allele
by loss of heterozygosity (LOH) simultaneously inacti-
vated both genes. In this model, all typical features of
astrocytoma progression from WHO grades II–IV were
observed, including invasion, new vessel formation,
multinucleated giant cells, necrosis, and subpial, perivas-
cular, and perineuronal satellitosis. As predicted for a
tumor suppressor, the wild-type allele was found to be
inactivated by LOH. This is a remarkable experiment,
exploiting gene knockout strategies and cancer genetics in
mice requiring no further manipulation. Penetration of the
disease phenotype might be enhanced by breeding these
mice with genetically unstable animals.
The Ras-only astrocytoma model displays
genetic instability
In contrast to the mouse model presented by Holland et al.
[45] in which an activated Ras gene alone was not
tumorigenic but only in combination with activated Akt, a
mouse model was recently introduced that gives rise to
rapidly growing malignant astrocytomas relying only on
activated Ras [24]. In this model, transgenic animals were
created as chimeras taking advantage of transformed
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embryonic stem cells that overexpress mutant Ras under a
GFAP promoter. Two tumor-derived cell lines were
shown to harbor alterations typically seen in human
disease such as loss of p16INK4a and p19ARF expression
and high levels of CDK4 and MDM 2 due to trisomy 10,
which is syntenic to the human 12q13–14 region, and in
one case loss of the PTEN protein. It has to be clarified
whether the fundamental difference between these differ-
ent animal models with regard to the oncogenic potential
of the mutant Ras gene is simply due to variations in the
genetic background or if oncogenic activation of p21-Ras
can indeed lead to genomic instability.
The therapeutic value of murine glioma models
Taken together, these animal models represent very
significant progress in mimicking distinct features of the
human glioma phenotype by pinpointing the tumor-
inducing factors and pathways which are preferentially
targeted in human disease. It is an open question whether
these genetic murine glioma models will prove useful and
reliable for assessing therapeutic strategies to treat human
tumors or whether orthotopic models using human
glioblastoma cell lines will yield more reliable results.
A striking difference in human gliomas appears to be the
level of genomic instability as compared to the single-
and double-step tumorigenesis in these animal models,
although an exhaustive search for additional genetic
alterations possibly accumulated during tumorigenesis
has not been reported, except for some typical cancer
gene loci which were altered in Ras-only glioma mouse
[24]. Even though faithfully reiterating most phenotypic
features of human disease, the recombinatory potential of
human tumor cells is likely to be quantitatively and
qualitatively different from murine counterparts. Human
tumor cells harbor a potent mutation generator (see
below) which has not been described in these animal
models so far. Genetic versatility allows human tumor
cells to escape from virtually every therapeutic challenge.
This caveat might be overcome by crossing some of these
different glioma mice with animals harboring hemizygous
mutations in so-called caretaker genes, e.g., mlh1 and
msh2, or in recQ homologues such as blm or wernerin
that are associated with cancer [74, 104].
The many possible causes of the glioma mutator
phenotype—a missing pathway?
In contrast to cancer cells, DNA replication is exception-
ally accurate in normal cells [71]. Considering the rarity
of mutations in normal cells and the large number of
mutations observed in human cancers, the spontaneous
rate in the former cannot account for the large rate of the
latter. Carcinogenesis involves substantial errors in DNA
replication, deficits in DNA repair, and alterations in
chromosomal segregation, giving rise to a mutator
phenotype, as already envisioned in 1991 [70]. Concep-
tually, errors in DNA synthesis due to misincorporation of
nucleotides by DNA polymerases and inadequate repair
of DNA damage caused by exogenous or endogenous
reactive molecules can lead to this phenotype. The overall
mutation rate in somatic human cells has been estimated
at 1.41010 nucleotides/cell per division, which translates
into one mutant gene for each cell during an idividual’s
life span, based on 70,000 genes within the human
genome. This implies that a few of the 1014 cells per
human body will contain as many as 12 mutations,
according to a Poisson probability distribution [71]. The
slope of the exponential increase of cancer as a function
of age suggests that there are six to 12 cancer-causing
events [96], which could explain the increasing rate of
cancer with age. This rate, however, cannot explain the
high number of genetic alterations in cancer. The
hundreds, maybe thousands of clonal mutations detectable
in cancer tissue must occur due to a mutator mechanism
leading to chromosomal instability, hyper- and aneuploi-
dy, translocations, amplifications, loss of heterozygosity,
and microsatellite instability.
Four major overlapping pathways for the repair of
DNA lesions in human cells might be involved in the
generation of a mutator phenotype: nucleotide excision
repair, base excision repair, mismatch repair, and the
direct reversal of lesions by recombination [44, 71]. In
addition, subtly altered DNA polymerases might be
causative in generating a mutator phenotype in some
instances, e.g., one of the most inaccurate DNA synthe-
sizing enzymes, DNA polymerase b, confers genetic
instability and showed enhanced activity in several
cancers [8]. Furthermore, the mutant DNA helicases
BLM and WRN can be linked to cancer syndromes and
premature aging characterized by increased formation of
sister chromatid exchange in Bloom syndrome [74] or
large deletions in Werner’s syndrome [104], both un-
common autosomal recessive disorders. Future popula-
tion-based genetic studies will show whether subtle
alterations in any of these genes are linked to an increased
incidence of brain tumors and whether sporadic tumors
contain somatic mutations in any of these enzymes. A
fundamental question is whether the inability to respond
to DNA damage is a very early step in tumorigenesis that
is a prerequisite for the malignant transformation.
The most dangerous type of DNA damage is the
double strand break which results from exogenous agents
such as ionizing radiation and certain chemotherapeutic
drugs, endogenously generated reactive oxygen species,
and mechanical stress on the chromosomes [57]. A single
DNA double strand break can be sufficient to kill a cell if
it inactivates an essential gene or triggers apoptosis. In
addition, erroneous rejoining of broken DNA may occur,
leading to the loss or amplification of chromosomal
material or, under certain circumstances, translocations in
which segments of chromosomal arms are exchanged,
giving rise to tumorigenesis if a tumor suppressor or an
oncogene is involved. Two distinct and conserved mech-
anisms for double strand break repair have evolved—the
relatively error-free homologous recombination and error-
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prone nonhomologous end-joining. Mammalian Rad51
interacts with the tumor-suppressor and cell-cycle pro-
teins p53, Brca1, and Brca2, and other proteins have been
linked to homologous recombination in mammals such as
the protein kinase ATM [56], which is deficient in cancer
predisposition, radiosensitivity, and the neurodegenera-
tive syndrome ataxia-telangiectasia (A-T). Of note, A-T
carriers (ATM heterozygotes) constitute approximately
1% of the general population and are believed to carry a
3–5-fold increased risk of developing breast cancer. In
addition, ATM-related proteins (ATR) play a role in
genomic integrity [2]. Following DNA damage, E2F1 is
stabilized by ATM/ATR-mediated phosphorylation of the
N terminus [69]. Indeed, somatic mutations in ATR have
been detected in sporadic stomach tumors with mi-
crosatellite instability [83]. In the Werner’s [104] and
Bloom [74] syndromes, deficient DNA helicases cannot
sufficiently suppress illegitimate recombination, which
they normally prevent during homologous recombination.
In addition, these DNA helicases are unique in their
ability to disrupt G-quadruplex DNA, non-Watson-Crick
structures that can form within guanine-rich DNA
sequences such as telomeric repeats, which is critical
for telomere maintenance [66]. The mismatch repair
protein MLH1 has recently been found to interact with
BLM in a poorly defined postreplicative repair mecha-
nism, since no microsatellite instability was detected in
BLM-deficient cells [91]. Other proteins involved in
double strand break repair are DNA protein kinases,
phosphatidyl inositol 3-kinase-related kinases (PIKK),
which includes ATM, ATR, and transactivation/transfor-
mation domain-associated protein (TRRAP9, and nibrin
(Nbs1) and MRE11, genes mutated in the ATM-like
disorders [15]. MRE11 associates with E2F family
members via the Nbs1 N terminus, suppressing double
strand breaks [20] by its influence on regulation and
progression of DNA replication (Fig. 3) [80]. TRRAP is a
cofactor of c-Myc- and E2F-mediated oncogenic trans-
formation, part of histone acetyltransferase complexes,
and essential for cell cycle progression [41, 82]. The large
number of proteins that participate in the recombination
machinery, for example altering the acetylation state of
histones or remodeling chromatin, can be regarded as
members of the class of “genome caretakers” which act to
maintain genetic stability.
Our knowledge about the involvement of DNA repair
genes in glioma tumorigenesis is limited. It has been
shown that gliomas are surrounded by normal cells
defective in the repair of DNA damage by alkylating
agents, implying the lack of O6-methylguanine-DNA
methyltransferase (MGMT) production as a predisposing
factor for the development of brain tumors [107]. In
contrast, MGMT protein is significantly elevated in
malignant brain tumor tissue, conferring resistance to-
wards alkylating agents [108]. A correlation between
MGMT expression and chemoresponse was also de-
scribed in temodal-treated glioblastomas [31]. For ho-
mologous recombination-mediated repair of DNA
damage induced by alkylating agents, mismatch repair
cooperates with MGMT and might be epigenetically
inactivated, as shown for hMSH6 [6, 123]. Apurinic/
apyrimidinic endonuclease Ape-1 activity was described
to be elevated, too, in human gliomas, also conferring
resistance to ionizing radiation and alkylating agents [10].
Interestingly, the rare Turcot’s syndrome, which is
defined by comanifestation of colorectal cancer and glial
neoplasm within the context of the hereditary nonpoly-
posis colorectal cancer syndrome (HNPCC), represents a
true inherited mutator phenotype and can, in some
glioblastoma cases [38], have a better clinical course
[85]. Sporadic mismatch repair deficiency can rarely be
detected in typical sporadic glioblastomas at a frequency
clearly beyond 1% (unpublished observation). The mis-
match repair phenotype is mostly caused by mutant
human mutS homologue 2 (hMSH2) or mutH homologue
1 (hMLH1), which constitute the replicative multiprotein
mismatch repair complex operative during cellular repli-
cation [52]. These two proteins have been found to be
expressed at various levels in glioblastomas and not
clearly correlated with therapeutic response to alkylating
agents [31]. No clear correlation was detected for ATM
expression and radioresistance in glioma cell lines, either
[17]. An analysis of the genetic status of glioma patients
was not performed; however, the role of ATM might be
distinct in tumor induction at a very early stage as
compared to radioresistance.
Practical consequences from understanding
the glioma mutation generator
If indeed most “sporadic” gliomas occurred in a selected
number of individuals that carry subtle mutations in
enzymes responsible for the integrity of the genome, it
would become possible to identify persons at risk by
focused screening programs years before gliomas become
clinically manifest. Such a scenario is realistic, even
though tools for detecting early disease stages will have to
be improved. Treatment aiming at eradicating full-blown
glioblastoma appears highly difficult, given the infiltra-
tive nature of the disease, which harbors invasive cell
clusters deeply beyond visible tumor margins. Early
detection might render glioblastomas amenable to more
successful interventions at more favorable stages with
much lower tumor burden.
Unchecked invasiveness—a key factor
of glial malignancy
Growth factors and Rac-dependent migration
PDGF can stimulate migration of oligodendrocyte pro-
genitor cells [110], neonatal rat cortical astrocytes [13],
and embryonic rat neural stem cells [29]. PDGF signals
through PI3K and PLC-g [98]. EGFR autocrine signaling
induces cell scattering and migration in glioma cells in
vitro [53], and glioma cells expressing mutant DEGFR
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show enhanced invasiveness when implanted in mouse
brain [86]. G-protein-coupled receptors play a role in
growth factor-mediated migration by cross-talking with
the tyrosine kinase receptor in a positive feedback loop
and enhancing signaling via the small GTPase Rac [43].
Of note, Rac seems to be negatively regulated by merlin,
the neurofibromatosis type II (NF-2) tumor suppressor
that predisposes humans and mice to tumor development
[103]. The NF-2-encoded protein, merlin, belongs to the
ERM (ezrin, radixin, and moesin) family of cytoskele-
ton:membrane linkers (Fig. 3, Fig. 5).
p16INK4a, PTEN, and invasion
PTEN modulates migration via PIP3 levels as a negative
regulator of PI3K that channels into the PI-3K-Rac-Rho
pathway [19, 109]. In addition, PTEN has been shown to
strongly suppress glioma invasiveness independently of
its catalytic domain, a finding that requires further
experimental workup [78]. Invasion also appears to be
regulated by p16INK4a. In a recent study, expression of
full-length p16INK4a was found to block avb3 integrin-
dependent cell spreading on vitronectin, ascribing a novel
function to the p16INK4a tumor suppressor protein in
regulating matrix-dependent cell migration [27].
Integrin and EGFR signaling converging
at the focal adhesion kinase
Glioma cells perform their widespread and devastating
invasion of normal brain tissue along white matter tracts
and perivascular spaces. These tumor cells are resistant to
anoikis, reflecting independence from integrin signaling.
In normal cells, loss of substrate attachment leads to the
induction of apoptosis, or anoikis [32]. There are
obviously differences in invasiveness between different
grades and from tumor to tumor which are difficult to
assess objectively, as there are no parameters yet to
measure the extent and dynamics of tumor cell infiltra-
tion. One such parameter is FAK, which appears to be a
key mediator of cell shape and motility. It is required for
integrin-dependent signaling and modulates cellular ad-
hesion, migration [49], and survival [48]. With respect to
tumor formation, decreased expression of FAK was
shown to suppress papilloma formation during murine
skin carcinogenesis [81]. FAK is targeted to the focal
adhesions by the C-terminal focal adhesion targeting
domain (FAT), promoting phosphorylation of tyrosine-
397 (Tyr397), which is essential for FAK activity. FAK
could not be confirmed as a substrate of PTEN [78], as
initially proposed [118]. In a recent analysis of the
expression of FAK in human gliomas, FAK immunore-
activity was detected in all astrocytomas of grades II–IV
and was significantly increased in glioblastomas and
gemistocytic low-grade astrocytomas, which have a more
ambiguous prognosis, while it was virtually absent from
Fig. 5 Migration and survival
pathways in gliomas. The major
receptor tyrosine kinases EGFR
and PDGFR mediate migratory
and survival cues into the cell
via FAK/CAS/Crk/Rac and
Ras/MEK/ERK. ERK enters the
nucleus and induces a promi-
gratory program but also pro-
motes invasion via MLCK.
ERK and PKB change gene
transcription, which is possibly
responsible for altered expres-
sion of some inhibitors of ap-
optosis and Blc-homologous
genes
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the more “benign” oligodendrogliomas [54]. FAK was
observed in all astrocytic cell compartments (cell soma
and astrocytic processes) and often highly localized at the
cell membrane. A low degree of FAK immunoreactivity
in oligodendrogliomas is an intriguing observation that
raises the question of whether FAK can be regarded as a
useful prognostic marker to predict the dynamics of
glioma invasiveness. Oligodendroglioma cells do also
infiltrate the surrounding normal brain, however with
different dynamics than those of astrocytic tumors. FAK
expression appears to be related to tumor progression,
since immunoreactivity was found to be higher in
recurrent glioblastoma than in primary lesions. Increased
FAK expression has been shown to increase expression of
the inhibitor of apoptosis (IAP) gene family (cIAP1,
cIAP2, XIAP) by activating PI-3 K/PKB and NF-kB,
further elevating the apoptotic threshold [112]. Inactivat-
ing FAK using the C-terminal dominant negative FAT
domain of FAK leads to decreased transcription of cIAP1,
cIAP2, XIAP, and FAK itself in glioblastoma cells [54].
The expression of these inhibitory proteins of apoptosis is
mediated by either PI3K/PKB and/or Ras/MEK/ERK
(Fig. 5). The molecular mechanism of FAK upregulation
in glioblastomas is not elucidated yet and could well
result from a loss in function mutation of a regulatory
gene, since no genetic alterations have been detected in
the FAK gene (unpublished data, G. Reifenberger).
Inactivation of FAK leads to attenuation of EGFR
phosphorylation and enhances the degradation of EGFR
in a ubiquitin-dependent way [54]. While some FAK
effects are linked to EGFR signaling and could also be
blocked by EGFR-specific tyrosine kinase inhibitors, the
integrin-dependent part of the signal flow might be more
directly blocked by targeting FAK. Two FAK-dependent
pathways have recently been proposed that signal either
via CAS/Crk/Rac to mediate invasion and survival or via
Ras/Raf/MEK/ERK [18]. ERK further modulates myosin
light chain kinase (MLCK) or directly enters the nucleus
to alter gene transcription. A modified scheme is
presented in Fig. 5. Fundamental cell fate decisions like
migration and survival or anoikis are intimately linked
and use several alternating pathways.
Conclusion
Dramatic progress in glioma genetics and tumor and
developmental biology has allowed the establishment of
several glioma mouse models that faithfully mimic
hallmarks of the various glioma subtypes. Autocrine
PDGF stimulation seems to favor oligodendrocytic
differentiation, while Ras alone or in conjunction with
an activated Akt allele gives rise to astrocytic tumors.
Remarkable is a compound heterozygotic cis double
knockout model in which both p53 and the negative Ras
regulator neurofibromin are simultaneously inactivated,
reiterating all stages of astrocytoma progression from
WHO grades II to IV. The small inhibitory cell cycle
regulators p27 and p16INK4a/p14(p19 in mice)ARF are not
tumorigenic per se but act as powerful progressive factors
accelerating proliferation and increasing malignancy in
humans and mice alike [4]. The degree of genomic
instability in these animal models might be quite different
from the human disease and lead to distinct responses to
pharmacological intervention. The genes that drive the
glioma mutator phenotype and give rise to the increased
mutational load await to be unraveled and might pave the
way for early detection of these devastating lesions.
Novel pharmacological approaches have started to exploit
tumor-specific alterations of the cell signaling network,
defining EGFR, PDGFR, FAK, PI-3 K, PKB/Akt-1,
mTOR, and others as prime targets for small drug
interventions.
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